Clinical trial
Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV…
NCT00010309 · Genzyme, a Sanofi Company, Industry · Unknown status
Key facts
| NCT number | NCT00010309 |
|---|---|
| Title | Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma |
| Official title | Phase I/II Trial Investigating The Safety And Immunogenicity Of Adenoviruses Encoding The Melan-A/MART-1 And gp 100 Melanoma Antigens Administered Intradermally To Patients With Stage II-IV Melanoma |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Unknown status |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | MART-1 antigen, gp100 antigen |
| Start date | Nov 1, 2000 |
| First posted | Nov 11, 2003 |
| Last update posted | Jan 6, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: